Annals of Surgical Oncology Sign the Guestbook
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haase, G. M.
Right arrow Articles by Matthay, K. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haase, G. M.
Right arrow Articles by Matthay, K. K.

Annals of Surgical Oncology, Vol 2, Issue 6 516-523, Copyright © 1995 by Society of Surgical Oncology

ARTICLES

Pelvic neuroblastoma--implications for a new favorable subgroup: a Children's Cancer Group experience

G. M. Haase, M. C. O'Leary, D. O. Stram, J. N. Lukens, R. C. Seeger, H. Shimada and K. K. Matthay
Department of Pediatric Surgery, University of Colorado, Denver 80218, USA.

BACKGROUND: The survival in neuroblastoma is influenced by patient age, disease stage, tumor site, and several biologic factors. This study was undertaken to determine if primary pelvic lesions are associated with an unusually favorable outcome. METHODS: Nine hundred eighty-six patients registered on Children's Cancer Group studies from 1980 to 1993 were reviewed, and 41 (4.3%) were found to have pelvic tumors. Survival was analyzed, and correlations among age, stage of disease, surgical resectability, histopathology, serum ferritin, and N-myc oncogene amplification were evaluated. RESULTS: Age at diagnosis was comparable between patients with pelvic and nonpelvic tumors. Disease distribution was similar, with stages III and IV comprising 78% (32 of 41) of pelvic lesions compared with 73% (692 of 945) for nonpelvic tumors. There was no outcome difference in favorable stages (I, II, and IV-S), with 3-year progression-free survival rates of 88% and 82% for pelvic and nonpelvic sites, respectively. However, in stages III and IV, the 3-year progression-free survival was 70% for pelvic lesions compared with 47% for nonpelvic tumors (p = 0.04). Some favorable biologic factors were more common in children with pelvic lesions. CONCLUSIONS: The pelvis is an unusual primary site for neuroblastoma but represents a more favorable prognostic subgroup, which is most evident in advanced-stage disease.


This article has been cited by other articles:


Home page
 JCOHome page
M.-D. Leclair, O. Hartmann, Y. Heloury, L. Fourcade, A. Laprie, F. Mechinaud, C. Munzer, and H. Rubie
Localized Pelvic Neuroblastoma: Excellent Survival and Low Morbidity With Tailored Therapy--The 10-Year Experience of the French Society of Pediatric Oncology
J. Clin. Oncol., May 1, 2004; 22(9): 1689 - 1695.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
S. Yokoyama, H. Hirakawa, S. Ueno, H. Yabe, and N. Hiraoka
Neuroblastoma of the Urinary Bladder, Preclinically Detected by Mass Screening
Pediatrics, May 1, 1999; 103(5): 67e - 67.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1995 by the Society of Surgical Oncology.